Advanced Search

Project: Aflibercept for neovascular age-related macular degeneration (2016)

Public Report Complete



Project Summary

Title and Description

Title Aflibercept for neovascular age-related macular degeneration (2016)
Description To assess and compare the effectiveness and safety of intravitreal injections of aflibercept versus ranibizumab, bevacizumab, or sham for treatment of patients with neovascular AMD.
  • Comments Comments (
    0
    ) |
Contributor(s) Sarwar S, Clearfield E, Soliman MK, Sadiq MA, Baldwin AJ, Hanout M, Agarwal A, Sepah YJ, Do DV, Nguyen QD. Aflibercept for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2016, Issue 2. Art. No.: CD011346. DOI: 10.1002/14651858.CD011346.pub2.
  • Comments Comments (
    0
    ) |
Methodology SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (Issue 11, 2015), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to November 2015), EMBASE (January 1980 to November 2015), PubMed (1948 to November 2015), Latin American and Caribbean Health Sciences Literature Database (LILACS) (1982 to November 2015), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com) (last searched December 4, 2014), ClinicalTrials.gov (www.clinicaltrials.gov), and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic search for trials. We last searched the electronic databases on November 30, 2015. SELECTION CRITERIA: We included randomized controlled trials (RCTs) in which aflibercept monotherapy was compared with ranibizumab, bevacizumab, or sham for participants with neovascular AMD who were treatment-naive. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures of The Cochrane Collaboration for screening, data abstraction, and study assessment. Two review authors independently screened records, abstracted data, and assessed risk of bias of included studies; we resolved discrepancies by discussion or with the help of a third review author when needed.
  • Comments Comments (
    0
    ) |
DOI
  • Comments Comments (
    0
    ) |
Funding Source Grant 1 U01 EY020522, National Eye Institute, National Institutes of Health, USA
  • Comments Comments (
    0
    ) |
Notes Available on PubMed at https://www.ncbi.nlm.nih.gov/pubmed/26857947 Data retrospectively entered into SRDR for public accessibility.
  • Comments Comments (
    0
    ) |

Key Questions

1 What is the effect of Aflibercept for treating neovascular age-related macular degeneration?
  • Comments Comments (
    0
    ) |

Associated Extraction Forms

Title Created by Key Questions Addressed Form Notes
Aflibercept for neovascular age-related macular degeneration Long Long 1


Associated Studies (each link opens a new tab)

Title Author Year
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Heier JS., Brown DM., Chong V., Korobelnik JF., Kaiser PK., Nguyen QD., Kirchhof B., Ho A., Ogura Y., Yancopoulos GD., Stahl N., Vitti R., Berliner AJ., Soo Y., Anderesi M., Groetzbach G., Sommerauer B., Sandbrink R., Simader C., Schmidt-Erfurth U. 2012
Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration Heier JS, Brown DM, Chong V, Korobelnik J-F, Kaiser PK, Nguyen QD, et al 2012




Creative Commons LicenseThis graphic notice indicates that you are leaving this Federal Government Web site and entering a non-Federal Web site. Creative Commons  
The data contained in this project are distributed under the terms of the Creative Commons Attribution-NonCommerical license, which permits the use, dissemination, and reproduction in any medium, provided the original work is properly cited, and that the use is non-commercial and otherwise in compliance with the license. See: https://creativecommons.org/licenses/by-nc/3.0/